- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Grifols SA - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| Di | GRIFOLS, S.A.: Grifols hereby reports that the Notes have been issued and that the private placement has been closed successfully. | 15 | CNMV | ||
| 23.04. | GRIFOLS, S.A.: The Company reports the signing subject to customary closing conditions of the private offering of EUR 1 billion of senior secured notes. | 50 | CNMV | ||
| 19.04. | Biotest baut aus, während Grifols weiter mit Gotham-Schatten kämpft. Ist die Mutter die spannendere Aktie? | 591 | Nebenwerte Magazin | Biotest hat in Wuppertal das 12. Plasmasammel-zentrum in Deutschland offiziell eröffnet. Klares Wachstumsprogramm ganz nach den Wünschen der Hauptaktionärin Grifols, die zuletzt von Shortsellern unter... ► Artikel lesen | |
| 18.04. | Grifols SA - 6-K, Report of foreign issuer | 8 | SEC Filings | ||
| 18.04. | Grifols, S.A.: Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. | 6 | GlobeNewswire (USA) | ||
| 18.04. | GRIFOLS, S.A.: Change of Secretary of the Company's Audit Committee. | 7 | CNMV | ||
| 15.04. | Grifols reportedly looking to appoint independent directors | 13 | Seeking Alpha | ||
| 14.04. | Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper | 25 | Reuters | ||
| 10.04. | Grifols SA - 6-K, Report of foreign issuer | 16 | SEC Filings | ||
| 10.04. | Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake | 26 | Reuters | ||
| 10.04. | Grifols Plans First Bond Sale Since Short Seller Gotham's Attack | 22 | BNN Bloomberg | ||
| 10.04. | GRIFOLS, S.A.: Grifols S.A. wishes to inform the market that it is actively pursuing the raising of senior secured notes, the proceeds of which (if successful) will be used to refinance its unsecured notes due 2025. | 16 | CNMV | ||
| 04.04. | Spain's Grifols gives new details on past EBITDA, leverage ratios to supervisor | 46 | Reuters | ||
| 04.04. | GRIFOLS, S.A.: Grifols presents the information requested by the CNMV. | 20 | CNMV | ||
| 04.04. | Grifols, S.A.: Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening | 438 | GlobeNewswire (Europe) | Grifols' in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections
Arboviruses are a growing emerging threat, with changes in... ► Artikel lesen | |
| 04.04. | Grifols, S.A.: Grifols Procleix ArboPlex Assay® erhält die CE-Zertifizierung - der erste und einzige 4-in-1-Nukleinsäuretest zum Nachweis von Arboviren | 283 | GlobeNewswire (Deutschland) | Der In-vitro-Nukleinsäuretest von Grifols weist vier Arten von Arboviren nach und trägt dazu bei, das Risiko transfusionsbedingter Infektionen zu verringernArboviren stellen eine wachsende Bedrohung... ► Artikel lesen | |
| 02.04. | Grifols SA - 6-K, Report of foreign issuer | 17 | SEC Filings | ||
| 02.04. | GRIFOLS, S.A.: Mr. José Ignacio (Nacho) Abia holds the category of "executive director". | 25 | CNMV | ||
| 01.04. | New Olympus Americas CEO takes corner office after former CEO joins Grifols | 24 | MassDevice |
Seite:
1 2 3 4 5 Weiter >>
195 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MERCK KGAA | 150,30 | +0,91 % | Merck KGaA-Aktie leicht im Plus (150,95 €) | Der Anteilsschein von Merck notiert heute fester. Die Aktie notiert derzeit bei 150,95 Euro. Am deutschen Aktienmarkt hat sich heute die Merck-Aktie zwischenzeitlich um 0,57 Prozent verteuert. Der Kurs... ► Artikel lesen | |
| GSK | 20,130 | +3,02 % | UBS stuft GSK auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für GSK mit einem Kursziel von 2040 Pence auf "Buy" belassen. Analyst Jo Walton rechnet in seinem am Montag vorliegenden Ausblick... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 373,85 | +0,25 % | Vertex Pharmaceuticals: Vertex Announces European Commission Approval for KALYDECO to Treat Infants With Cystic Fibrosis Ages 1 Month and Older | KALYDECO is the first and only medicine approved in the EU in this age group to treat the underlying cause of cystic fibrosis for specific mutations in the CFTR gene - Vertex Pharmaceuticals... ► Artikel lesen | |
| BAUSCH HEALTH | 7,500 | -0,62 % | Bausch Health Companies Inc.: Bausch Health Announces First Quarter 2024 Results | First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basisYear-over-year revenue growth in all segments on both a Reported and Organic1 BasisGAAP Net Loss Attributable... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 142,50 | +1,79 % | Alnylam Pharmaceuticals Inc. Q1 Loss Decreases, beats estimates | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) revealed Loss for first quarter that decreased from last year and beat the Street estimates.The company's bottom line totaled -$65.94... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 1,577 | +1,61 % | Nektar Network Begins Epoch 1 of Nektar Drops - Rewards for Ongoing Participation | ||
| APONTIS PHARMA | 8,280 | +0,24 % | Original-Research: Apontis Pharma AG (von Montega AG): Kaufen | Original-Research: Apontis Pharma AG - von Montega AG Einstufung von Montega AG zu Apontis Pharma AG Unternehmen: Apontis Pharma AG ISIN: DE000A3CMGM5 Anlass der Studie: Update Empfehlung:... ► Artikel lesen | |
| MEDPACE | 372,10 | +2,08 % | Medpace Holdings Insider Trades Send A Signal | ||
| EXMCEUTICALS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.12.2023 | The following instruments on Boerse Frankfurt do have their last trading day on 13.12.2023Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.12.2023ISIN NameCA30207T1049 EXMCEUTICALS... ► Artikel lesen | |
| CANTOURAGE GROUP | 7,450 | -4,49 % | PTA-DD: Cantourage Group SE: Mitteilung über Eigengeschäfte von Führungskräften gemäß Artikel 19 MAR | DJ PTA-DD: Cantourage Group SE: Mitteilung über Eigengeschäfte von Führungskräften gemäß Artikel 19 MAR
Eigengeschäfte von Führungskräften gemäß Artikel 19 MAR
Berlin (pta/12.04.2024/16:38)... ► Artikel lesen | |
| TITAN PHARMACEUTICALS | 6,530 | +3,81 % | Titan Pharmaceuticals, Inc.: Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria | SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that by letter dated January 24, 2024, the Company... ► Artikel lesen | |
| SCYNEXIS | 1,583 | -4,64 % | SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID) | In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a broad range of pathogenic fungi, including... ► Artikel lesen | |
| INVENTIVA | 2,990 | -0,33 % | INVENTIVA: Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F | Daix (France), Long Island City (New York, United States), April 3, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| CHAMPIONS ONCOLOGY | 4,480 | -0,44 % | Champions Oncology, Inc.: Champions Oncology Reports Quarterly Revenue of $12.0 Million | HACKENSACK, NJ / ACCESSWIRE / March 12, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced... ► Artikel lesen | |
| GABATHER | 0,133 | -7,96 % | Gabather AB: Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002 | STOCKHOLM, April 10, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) announces that the Company has signed a Collaborative Agreement with the Centre for Neuropsychiatric... ► Artikel lesen |
Das Unternehmen GRIFOLS SA ADR 1/2/EO kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,98 % bei einem Aktienkurs von 4,120 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
